Related Experiment Video
Updated: Feb 24, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.1K
New perspectives on CKD-induced dyslipidemia.
Marcelino Bermúdez-López1, David Arroyo1, Àngels Betriu1
1a Vascular and Renal Translational Research Group , Institute for Biomedical Research of Lleida (IRBLleida), REDinREN del ISCIII , Lleida , Spain.
Expert Opinion on Therapeutic Targets
|August 23, 2017
Summary
Chronic kidney disease (CKD) patients exhibit unique lipid alterations, increasing cardiovascular risk beyond standard measures. Advanced lipid profiling and lipidomics offer new targets for personalized management and improved risk assessment in these individuals.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Lipid Metabolism
Background:
- Chronic kidney disease (CKD) is a global health issue linked to increased cardiovascular disease (CVD) risk.
- Traditional lipid profiles inadequately explain the accelerated atherosclerosis seen in CKD patients.
- Lipoprotein alterations in CKD are complex and contribute significantly to CVD morbidity and mortality.
Purpose of the Study:
- To review the role of lipids in CKD-related atherosclerosis.
- To highlight CKD-induced alterations in lipoprotein metabolism.
- To explore advanced lipid analysis techniques and their therapeutic potential in CKD.
Main Methods:
- Literature review of prevailing knowledge on lipids and atherosclerosis in CKD.
- Overview of lipoprotein metabolism and CKD-specific changes.
- Analysis of novel technologies like lipoprotein subfraction profiling and lipidomics.
Main Results:
- CKD patients display distinct quantitative and qualitative lipid alterations not detected by routine tests.
- These alterations contribute to the elevated cardiovascular risk in CKD.
- Lipoprotein particle number, size, and novel lipidomic biomarkers offer personalized risk assessment.
Conclusions:
- CKD-induced dyslipidemia is a key driver of cardiovascular risk.
- Advanced lipid profiling and lipidomics provide deeper insights beyond traditional parameters.
- These novel approaches can personalize cardiovascular risk management for CKD patients.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
760
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
760
01:28Chronic Kidney Disease III: Interprofessional Care
503
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
01:25Chronic Kidney Disease I: Introduction
832
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
832
01:30Coronary Artery Disease I: Introduction
1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
01:26Atherosclerosis III: Management
476
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K